-
公开(公告)号：US11839618B2
公开(公告)日：2023-12-12
申请号：US14879857
申请日：2015-10-09
发明人： Noriko Koizumi , Shigeru Kinoshita , Morio Ueno
IPC分类号： A61K31/551 , A61K9/00 , A61K31/496 , C07D213/81 , C07D401/12 , C12N5/079 , A61K31/4409
CPC分类号： A61K31/551 , A61K9/0048 , A61K31/4409 , A61K31/496 , C07D213/81 , C07D401/12 , C12N5/0621 , C12N2501/70
摘要： The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.
-
公开(公告)号：US11633404B2
公开(公告)日：2023-04-25
申请号：US14879658
申请日：2015-10-09
发明人： Noriko Koizumi , Shigeru Kinoshita , Morio Ueno
IPC分类号： A61K31/551 , A61K9/00 , A61K31/496 , C07D213/81 , C07D401/12 , C12N5/079 , A61K31/4409
摘要： The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.
-
公开(公告)号：US11918630B2
公开(公告)日：2024-03-05
申请号：US15523282
申请日：2015-10-30
申请人： KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION , THE DOSHISHA , SENJU PHARMACEUTICAL CO., LTD.
发明人： Noriko Koizumi , Naoki Okumura , Shigeru Kinoshita
CPC分类号： A61K38/39 , A61K9/0048 , A61K31/4409 , A61K35/30 , A61K45/00 , A61K45/06 , A61P27/02 , A61K38/39 , A61K2300/00 , A61K31/4409 , A61K2300/00 , A61K35/30 , A61K2300/00
摘要： The present invention provides a technique for treating retinal epithelium and/or nerves. More specifically, the present invention is an agent for the treatment or prevention of retinal disease or the like and/or a disease, disorder, or ophthalmological state of the nerves, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with retinal pigment epithelial cells and/or nerve cells. Specifically, the present invention can include laminin 411 (α4β1γ1), laminin 511 (α5β1γ1), laminin 521 (α5β2γ1), or fragments of these.
-
公开(公告)号：US11633477B2
公开(公告)日：2023-04-25
申请号：US15523231
申请日：2015-10-30
申请人： KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION , THE DOSHISHA , SENJU PHARMACEUTICAL CO., LTD.
发明人： Noriko Koizumi , Naoki Okumura , Shigeru Kinoshita
IPC分类号： A61K45/00 , A61K31/4409 , A61K35/30 , A61K38/39 , A61K35/44 , A61K31/137
摘要： The present invention provides a technique for treating the cornea. More specifically, the present invention is an agent for the treatment or prevention of a state of corneal endothelial disease, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with corneal endothelial cells. Specifically, the present invention can include laminin 511 (α5β1γ1), laminin 521 (α5β2γ1), or a fragment of these.
-
公开(公告)号：US20170202910A1
公开(公告)日：2017-07-20
申请号：US15443913
申请日：2017-02-27
申请人： Kyoto Prefectural Public University Corporation , The Doshisha , Senju Pharmaceutical Co., Ltd.
发明人： Takahiro Nakamura , Noriko Koizumi , Naoki Okumura , Shigeru Kinoshita , Kana Tominaga , Satoshi Kawasaki
IPC分类号： A61K38/17
CPC分类号： A61K38/1709 , A61K35/30 , A61K38/00 , A61K48/00 , C07K14/705 , C12N5/0621 , C12N2501/40 , C12N2501/415 , C12Q1/6881 , C12Q2600/158 , G01N33/56966 , G01N2333/726 , G01N2800/16
摘要： The present invention relates to a differentiation marker and a differentiation controlling technique for an eye cell. More particularly, the present invention has attained an object of providing a differentiation marker for an eye cell among the aforementioned problems, by providing a marker for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, the marker comprising GPR49/LGR5, as well as a detection agent or detection method for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, comprising a substance binding to GPR49/LGR5. In addition, the present invention has attained an object of providing a differentiation controlling technique for an eye cell, by providing an agent for suppressing differentiation and/or promoting proliferation of an eye cell, comprising R-spondins.
-
公开(公告)号：US09616101B2
公开(公告)日：2017-04-11
申请号：US14413066
申请日：2013-07-03
申请人： Kyoto Prefectural Public University Corporation , The Doshisha , Senju Pharmaceutical Co., Ltd.
发明人： Takahiro Nakamura , Noriko Koizumi , Naoki Okumura , Shigeru Kinoshita , Kana Tominaga , Satoshi Kawasaki
IPC分类号： A61K38/00 , A61K38/22 , A61K39/00 , C07K14/47 , C07K14/785 , C07K14/005 , A61K38/17 , A61K48/00 , C07K14/705 , A61K35/30 , G01N33/569 , C12N5/079 , C12Q1/68
CPC分类号： A61K38/1709 , A61K35/30 , A61K38/00 , A61K48/00 , C07K14/705 , C12N5/0621 , C12N2501/40 , C12N2501/415 , C12Q1/6881 , C12Q2600/158 , G01N33/56966 , G01N2333/726 , G01N2800/16
摘要： The present invention relates to a differentiation marker and a differentiation controlling technique for an eye cell. More particularly, the present invention has attained an object of providing a differentiation marker for an eye cell among the aforementioned problems, by providing a marker for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, the marker comprising GPR49/LGR5, as well as a detection agent or detection method for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, comprising a substance binding to GPR49/LGR5. In addition, the present invention has attained an object of providing a differentiation controlling technique for an eye cell, by providing an agent for suppressing differentiation and/or promoting proliferation of an eye cell, comprising R-spondins.
-
公开(公告)号：US20150202256A1
公开(公告)日：2015-07-23
申请号：US14413066
申请日：2013-07-03
申请人： Kyoto Prefectural Public University Corporation , The Doshisha , Senju Pharmaceutical Co., Ltd.
发明人： Takahiro Nakamura , Noriko Koizumi , Naoki Okumura , Shigeru Kinoshita , Kana Tominaga , Satoshi Kawasaki
CPC分类号： A61K38/1709 , A61K35/30 , A61K38/00 , A61K48/00 , C07K14/705 , C12N5/0621 , C12N2501/40 , C12N2501/415 , C12Q1/6881 , C12Q2600/158 , G01N33/56966 , G01N2333/726 , G01N2800/16
摘要： The present invention relates to a differentiation marker and a differentiation controlling technique for an eye cell. More particularly, the present invention has attained an object of providing a differentiation marker for an eye cell among the aforementioned problems, by providing a marker for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, the marker comprising GPR49/LGR5, as well as a detection agent or detection method for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, comprising a substance binding to GPR49/LGR5. In addition, the present invention has attained an object of providing a differentiation controlling technique for an eye cell, by providing an agent for suppressing differentiation and/or promoting proliferation of an eye cell, comprising R-spondins.
摘要翻译： 本发明涉及眼细胞的分化标记和分化控制技术。 更具体地，本发明通过提供用于鉴定角膜内皮细胞中具有高增殖能力的细胞和/或角膜分化能力的标记物，提供了上述问题中的眼细胞分化标记物的目的。 内皮细胞，包括GPR49 / LGR5的标记物，以及用于鉴定角膜内皮细胞中具有高增殖能力的细胞和/或角膜内皮细胞的分化能力的检测剂或检测方法，其包含与GPR49结合的物质 / LGR5。 此外，本发明通过提供用于抑制包含R-螺旋藻的眼细胞分化和/或促进增殖的试剂，已经达到了提供眼细胞分化控制技术的目的。
-
公开(公告)号：US11730722B2
公开(公告)日：2023-08-22
申请号：US14907881
申请日：2013-07-30
申请人： KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION , THE DOSHISHA , SENJU PHARMACEUTICAL CO., LTD.
发明人： Noriko Koizumi , Naoki Okumura , Shigeru Kinoshita
IPC分类号： A61K31/4439 , A61K39/395 , A61K31/519 , A61K31/4725 , A61K31/4745 , A61K31/4709 , A61K31/4402 , A61K45/06 , A61K9/00 , C12N15/113
CPC分类号： A61K31/4439 , A61K9/0048 , A61K31/4402 , A61K31/4709 , A61K31/4725 , A61K31/4745 , A61K31/519 , A61K39/395 , A61K45/06 , C12N15/1136 , C12N2310/14 , C12N2320/30 , A61K31/4402 , A61K2300/00 , A61K31/4725 , A61K2300/00 , A61K31/4745 , A61K2300/00 , A61K31/4709 , A61K2300/00 , A61K31/519 , A61K2300/00 , A61K39/395 , A61K2300/00
摘要： The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.
-
9.发明授权公开(公告)号：US11382904B2
公开(公告)日：2022-07-12
申请号：US15031183
申请日：2014-10-30
申请人： KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION , THE DOSHISHA , SENJU PHARMACEUTICAL CO., LTD.
发明人： Noriko Koizumi , Naoki Okumura , Shigeru Kinoshita
IPC分类号： A61K31/4439 , A61K31/444 , A61K31/4709 , A61K9/00 , A61K31/713 , A61K31/519 , A61K38/00 , A61K31/437 , A61K39/395 , C07K16/22
摘要： The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGFβ-signal inhibitor. As a preferred TGFβ-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.
-
公开(公告)号：US10959997B2
公开(公告)日：2021-03-30
申请号：US15108355
申请日：2013-12-27
申请人： KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION , THE DOSHISHA , SENJU PHARMACEUTICAL CO., LTD.
发明人： Noriko Koizumi , Naoki Okumura , Shigeru Kinoshita
IPC分类号： A61K31/4745 , A61K35/44 , A61K35/30 , A61K45/06 , A61K9/00
摘要： The present invention provides an agent for treating or preventing a disease, a disorder or a condition of a corneal endothelium, said agent comprising a corneal endothelial cell and a myosin II-specific inhibitor. More specifically, the myosin II-specific inhibitor is blebbistatin. The disease, the disorder or the condition is typically a disorder associated with Fuchs endothelial corneal dystrophy or corneal endothelial dysfunction (bullous keratopathy). Also provided is a method for treating or preventing a corneal endothelial disease, said method comprising a step of administering an effective amount of a myosin II-specific inhibitor together with a corneal endothelial cell to a subject.
-
-
-
-
-
-
-
-
-
搜索结果
61 条记录 (耗时 0.026 秒)
